PD-1/PD-L1抑制剂在HIV/AIDS合并癌症患者中的应用进展  

Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer

作　　者：邓长刚 张维 孙艳雨 李奇穗[1] 黄薇 袁婧[1] DENG Changgang;ZHANG Wei;SUN Yanyu;LI Qisui;HUANG Wei;YUAN Jing(Department of Infectious Disease,Chongqing Public Health Medical Center,Chongqing 400036,China)

机构地区：[1]重庆市公共卫生医疗救治中心感染科,重庆400036

出　　处：《肿瘤防治研究》2023年第9期924-928,共5页Cancer Research on Prevention and Treatment

摘　　要：目前免疫治疗已经成为癌症治疗的常见手段之一,其中PD-1/PD-L1抑制剂疗效显著。癌症及各种机会性感染是艾滋病患者常见的并发症。因该类患者的特殊免疫情况,多数癌症免疫治疗临床试验中,艾滋病作为一项排除标准,使免疫治疗在该类感染者中寸步难行。而高效抗反转录病毒治疗的普及使艾滋病感染者寿命不断延长,因而寻找免疫治疗在艾滋病合并癌症患者中的机遇迫在眉睫。Immunotherapy has become a common means of cancer treatment.In immunotherapy,PD-1/PD-L1 inhibitors have significant efficacy.Cancer and various opportunistic infections are common complications in patients with AIDS.Owing to the special immune situation of these patients,AIDS is regarded as an exclusion standard in most clinical trials for cancer immunotherapy,conferring immunotherapy difficulty in treating patients with AIDS.The popularity of effective antiretroviral drugs has prolonged the lifetime of people with AIDS.Therefore,exploiting the opportunity of using immunotherapy in AIDS with cancer is urgent.

关 键 词：PD-1/PD-L1抑制剂 艾滋病 人类免疫缺陷病毒 癌症 

分 类 号：R730.51[医药卫生—肿瘤]